– Oral presentation at ACR will highlight results from first head-to-head dose-ranging study comparing FX006 with approved injectable dose of commonly prescribed, immediate release steroid for patients with osteoarthritis (OA) of the knee –
– FX006 Provides Pain Relief Signal That is Among the Largest Seen in Osteoarthritis Clinical Trials –
– Optimal Dose for Phase 3 Trial Identified –
